Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C

Journal of Medical Virology

Volumn 83, Issue 7, 2011, Pages 1203-1211

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Tada, Toshifumi ^a   Kawaguchi, Takahisa ^b   Murakami, Yoshiki ^b   Matsuda, Fumihiko ^b  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amino acid substitution at residue 70 of the HCV core region; Chronic hepatitis C; Genetic polymorphism near the IL28B gene; Resistance to interferon

Indexed keywords

ALBUMIN; ARGININE; BILIRUBIN; GLUTAMINE; INTERLEUKIN 28B; PEGINTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DELIRIUM; DEPRESSION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETINOPATHY; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS CORE;

ANTIVIRAL AGENTS; CHROMOSOMES, HUMAN, PAIR 19; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; JAPAN; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 79955894224     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22092     Document Type: Article

References (19)

1. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380.
2. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410.
3. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007b. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79:1686-1695.
4. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2007c. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamic of viremia. Intervirology 50:361-368.
5. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. 2007. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 81:8211-8224.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
7. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335-1374.
8. Hayes NC, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K. 2011. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60:261-267.
9. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG. 2010. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138:2307-2314.
10. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. 1998. Progress of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 28:1687-1695.
11. Ohno O, Mizokami M, Wu R-R, Saleh MG, Ohba K-I, Orito E, Mukaide M, Williams R, Lau JY. 1997. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 35:201-207.
12. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 138:1338-1345.
13. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104.
14. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
15. The French Cooperative METAVIR Study Group. 1994. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20:15-20.
16. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. 2010. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139:120-129.
17. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Nakano S, Arakawa T, Fujimori M. 2009. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha. J Med Virol 81:1354-1362.
18. Toyoda H, Kumada T, Tada T, Arakawa T, Hayashi K, Honda T, Katano Y, Goto H. 2010a. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. J Gastroenterol Hepatol 25:1072-1078.
19. Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Takagi M, Hiramatsu T, Hosokawa T, Arakawa T, Fujimori M. 2010b. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1. J Med Virol 82:1537-1544.